

Table S1 – Baseline characteristics

	Insulin pump	MDI	All	p-value
No. of participants	10	10	20	na
Femal sex, %	60	60	60	1
Age, years	47 (23-64)	50 (24-63)	47	0.905
T1D duration, years	20 (8-58)	17 (3-44)	19	0.186
HbA1c, mmol/mol	53 (41-61)	50 (43-60)	51	0.570
HbA1c, %	7.0 (4.9-7.7)	6.7 (6.1-7.6)	6.8	0.570
BMI, kg/m ²	27.0 (21.6-36.4)	24.7 (21.6-29.6)	24.7	0.221
TDD, units	37 (24-65)	31 (20-48)	35	0.062
Insulin sensitivity factor, mmol/L/unit	2.5 (1.2-5.5)	1.9 (0.8-4.0)	2.3	0.126


Data presented as median (range). MDI; multiple daily injections. T1D; type 1 diabetes. HbA1c; glycated hemoglobin A1c. BMI; body mass index. TDD; total daily dose of insulin.

Table S2 – Baseline VAS scores

	CHO	D ₈₀	D ₁₂₀
Baseline VAS score (0-100)			
Nausea	0.6 (0.6)	0.7 (0.7)	2.3 (1.7)
Headache	2.5 (1.7)	2.4 (1.4)	3.6 (2.4)
Stomach-ache	0.0 (0.0)	0.0 (0.0)	0.5 (0.5)
Palpitations	0.6 (0.6)	0.7 (0.7)	0.0 (0.0)

Data presented as mean (s.e.m) VAS score at baseline (t=0). CHO; 15 g oral glucose intervention.

D₈₀; 80 µg dasiglucagon intervention. D₁₂₀; 120 µg dasiglucagon intervention. VAS; Visual Analog Scale.



Supplementary Figure S1 – Individual plasma glucose profiles from intervention (t=0) until the end of the three-hour observation period. White circles represent the 15 g oral glucose intervention, light

grey circles represent the 80 µg dasiglucagon intervention, and dark grey circles represent the 120 µg dasiglucagon intervention.